CD33xCD3 Bispecific Construct Step Dosing for AML
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia, particularly relapsed or refractory AML, face challenges with high toxicity and limited therapeutic efficacy due to cytokine release syndrome (CRS) associated with CD33×CD3 bispecific constructs, necessitating a safer and more effective administration schedule.
Innovation Solution
A bispecific construct with a CD33 binding domain and a CD3 binding domain is administered in a treatment cycle with multiple dosage steps over extended periods, allowing for gradual increase in dosage to mitigate CRS while maintaining therapeutic efficacy, including a first dosage of 10 μg/day, followed by escalating doses up to 1600 μg/day, with optional additional steps and treatment cycles without interruption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD33×CD3 bisspecific construct is administered at high dosage to achieve therapeutic efficacy, then treatment effectiveness is improved, but cytokine release syndrome (CRS) severity increases
Solution Approach 1:
The patent applies preliminary action by administering a low initial dosage (10 μg/day) of the CD33×CD3 bispecific construct before escalating to higher therapeutic doses. This gradual dose escalation over multiple treatment cycles allows the patient's immune system to adapt, thereby mitigating the severity of cytokine release syndrome while ultimately achieving the desired therapeutic efficacy at higher dose levels (up to 1600 μg/day).
Solution Approach 2:
The patent implements parameter changes by systematically varying the dosage parameter over time through multiple treatment cycles. The dosage is escalated from 10 μg/day in the first cycle to up to 1600 μg/day in subsequent cycles, with treatment-free periods interspersed between cycles. This dynamic parameter adjustment allows the therapy to balance between minimizing CRS (at lower doses) and maximizing therapeutic efficacy (at higher doses).
2Productivity
If continuous high-dose administration is used to maximize therapeutic effect, then treatment efficacy is improved, but toxicity and CRS risk increase
Solution Approach 1:
The patent applies periodic action by structuring the treatment as discrete treatment cycles separated by treatment-free periods. Each treatment cycle involves administering the bisspecific construct at escalating doses over a defined period (e.g., 28 days), followed by a treatment-free interval (e.g., 14 days). This periodic administration pattern allows the patient to recover from toxicity and CRS between cycles while accumulating therapeutic benefit over multiple cycles, thereby maximizing efficacy without overwhelming the system with continuous high-dose exposure.
3Loss of time
If dosage is escalated quickly to reach therapeutic level, then treatment time is reduced, but CRS severity increases
Solution Approach 1:
The patent applies preliminary action by using a low starting dosage (10 μg/day) in the first treatment cycle as a preparatory step before escalating to higher therapeutic doses in subsequent cycles. This gradual escalation strategy, while extending the overall treatment duration across multiple cycles, prevents severe CRS that would occur with rapid dose escalation, thereby optimizing the balance between treatment time and safety.
Data Source
AI summary
The present invention provides a bispecific construct comprising a first binding domain specifically binding to a target such as CD33 and a second binding domain specifically binding to an effector such as CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered in one or more treatment cycles of more than 14 days applying a step dosing comprising at least two, preferably steps, wherein the first step is higher than the second step with respect to the previous dosage, and wherein the second step is higher than the optional but preferred third step with respect to the previous dosage, a treatment cycle optionally followed by a period without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.